Continued Dosing of Oritavancin for Complicated Gram-Positive Infections

Jodi Meyer; Paul Lata; Susanne Barnett

doi:10.12788/fp.0068

Continued Dosing of Oritavancin for Complicated Gram-Positive Infections

Fed Pract. 2020 Nov;37(11):502-504. doi: 10.12788/fp.0068.

Authors

Jodi Meyer¹, Paul Lata¹, Susanne Barnett¹

Affiliation

¹ is a Doctor of Pharmacy candidate, and is an Associate Professor of Pharmacy, both at the University of Wisconsin. and Susanne Barnett are Clinical Pharmacists at William S. Middleton Memorial Veterans Hospital in Madison.

Abstract

Several retrospective and cohort analyses have suggested that continued dosing of oritavancin is both safe and efficacious for complicated Gram-positive infections, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.